Pfizer Inc on Tuesday said the final analysis of its antiviral Covid-19 pill still showed near 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.

The US drugmaker last month said the oral medicine was around 89% effective in preventing hospitalisations or deaths when compared to placebo based on interim results in around 1,200 people...